Global Information
회사소개 | 문의 | 위시리스트

Taiho Pharmaceutical Co., Ltd. : 제품 파이프라인 리뷰

Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 09월 상품 코드 240941
페이지 정보 영문 68 Pages
가격
US $ 1,500 ₩ 1,776,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,552,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,329,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Taiho Pharmaceutical Co., Ltd. : 제품 파이프라인 리뷰 Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
발행일 : 2016년 09월 페이지 정보 : 영문 68 Pages

Taiho Pharmaceutical Co., Ltd.는 일본에 본사를 둔 제약 기업으로, 알레르기, 면역계 질환, 암, 비뇨기 질환 분야에 대한 의약품, 항알레르기제, 항암제, H2 수용체 길항제 등의 제품을 취급하고 있습니다.

Taiho Pharmaceutical Co., Ltd.의 치료제 개발 파이프라인 현황과 각 개발 단계 비교 분석, 약제 표적, 작용기서, 투여 경로, 분자 종류별 치료제 평가, 최신 기업 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

목차

Taiho Pharmaceutical Co., Ltd.의 기본 정보

  • Taiho Pharmaceutical Co., Ltd.의 개요
  • 주요 정보
  • 기업 정보

Taiho Pharmaceutical Co., Ltd. : R&D 개요

  • 주요 치료 범위

Taiho Pharmaceutical Co., Ltd. : 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 단독요법
  • 병용요법 모달리티
  • 파트너 제품
    • 파트너 제품/병용요법 모달리티

Taiho Pharmaceutical Co., Ltd. : 파이프라인 제품 개요

  • 후기 단계 파이프라인 제품
    • 제Ⅲ상 제품/병용요법 모달리티
  • 임상 단계 파이프라인 제품
    • 제Ⅰ상 제품/병용요법 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 제품/병용요법 모달리티
    • 디스커버리 제품/병용요법 모달리티

Taiho Pharmaceutical Co., Ltd. : 치료제 개요

  • (tegafur + gimeracil + oteracil + calcium folinate)
  • (tegafur + gimeracil + oteracil)
  • bilastine
  • TAS-120
  • TAS-114
  • TAS-115
  • TAS-116
  • TAS-117
  • TAS-119
  • TAS-121
  • TAS-205
  • TAS-2913
  • TAS-2985
  • TAS-5567
  • Small Molecules to Inhibit S100B-p53 Interaction for Cancer

Taiho Pharmaceutical Co., Ltd. : 파이프라인 분석

  • 표적별
  • 투여 경로별
  • 분자 종류별
  • 작용기서별

Taiho Pharmaceutical Co., Ltd. : 최신 파이프라인 정보

Taiho Pharmaceutical Co., Ltd. : 개발 휴지중인 프로젝트

Taiho Pharmaceutical Co., Ltd. : 개발이 중지된 파이프라인 제품

  • 개발이 중지된 파이프라인 제품 개요

Taiho Pharmaceutical Co., Ltd. : 기업 이념

Taiho Pharmaceutical Co., Ltd. : 본사 및 자회사 소재지

  • 본사
  • 지사 및 자회사

부록

도표

KSM 15.12.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary

Global Markets Direct's, 'Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Taiho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Taiho Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Taiho Pharmaceutical Co., Ltd.
  • The report provides overview of Taiho Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Taiho Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Taiho Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Taiho Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Taiho Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Taiho Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Taiho Pharmaceutical Co., Ltd. Snapshot
    • Taiho Pharmaceutical Co., Ltd. Overview
    • Key Facts
  • Taiho Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Taiho Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Taiho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Taiho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Taiho Pharmaceutical Co., Ltd. - Drug Profiles
    • (calcium folinate + gimeracil + oteracil + tegafur) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (gimeracil + oteracil + tegafur) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (tipiracil hydrochloride + trifluridine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netupitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-116 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-119 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-3681 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-5567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trabectedin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Taiho Pharmaceutical Co., Ltd. - Dormant Projects
  • Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (gimeracil + oteracil + tegafur)
      • (tipiracil hydrochloride + trifluridine)
      • orantinib
      • suplatast tosilate
  • Taiho Pharmaceutical Co., Ltd. - Company Statement
  • Taiho Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Taiho Pharmaceutical Co., Ltd., Key Facts
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pre-Registration, 2016
  • Taiho Pharmaceutical Co., Ltd. - Phase III, 2016
  • Taiho Pharmaceutical Co., Ltd. - Phase II, 2016
  • Taiho Pharmaceutical Co., Ltd. - Phase I, 2016
  • Taiho Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016
  • Taiho Pharmaceutical Co., Ltd. - Preclinical, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
  • Taiho Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top
전화 문의
F A Q